GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CymaBay Therapeutics Inc (NAS:CBAY) » Definitions » Cash Flow from Investing

CymaBay Therapeutics (CymaBay Therapeutics) Cash Flow from Investing : $-86.57 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is CymaBay Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, CymaBay Therapeutics spent $0.18 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $115.93 Mil on purchasing investments. It gained $74.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, CymaBay Therapeutics spent $42.11 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


CymaBay Therapeutics Cash Flow from Investing Historical Data

The historical data trend for CymaBay Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CymaBay Therapeutics Cash Flow from Investing Chart

CymaBay Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.35 47.96 48.59 -45.99 -86.57

CymaBay Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.36 -60.64 0.72 15.46 -42.11

CymaBay Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

CymaBay Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

CymaBay Therapeutics's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CymaBay Therapeutics  (NAS:CBAY) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

CymaBay Therapeutics's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-0.18 Mil. It means CymaBay Therapeutics spent $0.18 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

CymaBay Therapeutics's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means CymaBay Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

CymaBay Therapeutics's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means CymaBay Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

CymaBay Therapeutics's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means CymaBay Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

CymaBay Therapeutics's purchase of investment for the three months ended in Dec. 2023 was $-115.93 Mil. It means CymaBay Therapeutics spent {stock_data.stock.currency_symbol}}115.93 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

CymaBay Therapeutics's sale of investment for the three months ended in Dec. 2023 was $74.00 Mil. It means CymaBay Therapeutics gained $74.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

CymaBay Therapeutics's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means CymaBay Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

CymaBay Therapeutics's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means CymaBay Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

CymaBay Therapeutics's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means CymaBay Therapeutics paid $0.00 Mil for other investing activities.


CymaBay Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of CymaBay Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


CymaBay Therapeutics (CymaBay Therapeutics) Business Description

Traded in Other Exchanges
Address
7575 Gateway Boulevard, Suite 110, Newark, CA, USA, 94560
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
Executives
Charles Mcwherter officer: Chief Scientific Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Daniel Menold officer: Vice President, Finance C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Paul T Quinlan officer: General Counsel C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Janet Dorling director C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Sujal Shah director, officer: Chief Executive Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Kurt Von Emster director 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Harish Shantharam officer: Chief Financial Officer 7575 GATEWAY BLVD, NEWARK CA 94560
Dennis D Kim officer: Chief Medical Officer C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803
Eric Lefebvre director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Thomas G Wiggans director
Lewis J Stuart officer: Chief Commercial Officer 3172 PORTER DRIVE, PALO ALTO CA 94304
Venbio Select Advisor Llc 10 percent owner 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh 10 percent owner C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Robert James Wills director 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103

CymaBay Therapeutics (CymaBay Therapeutics) Headlines

From GuruFocus